Japanese studio Toho is expanding its horror production slate with an exciting sci-fi survival thriller. Titled Leviathan, the intense space-set feature adapts Shiro Kuroi’s best-selling manga. The studio previously earned widespread international acclaim for hits like Godzilla Minus One and Exit 8. Currently in post-production, the adaptation promises a grim, highly suspenseful journey through deep space. Sci-fi horror fans can anticipate a brutal fight for survival set against a futuristic backdrop.
A Fatal Race for Life Support
The story takes place in 2127 aboard a damaged starship. After a catastrophic accident leaves a traveling vessel adrift, thirty-eight students find themselves hopelessly stranded in deep space. Dwindling oxygen creates an immediate crisis for the desperate teenagers onboard. The situation turns deadly when they discover only a single functioning life-support system remains. The surviving passengers turn against each other in a bloody battle to secure that one chance to live.
Uncovering the Tragic Logs
The original manga framing story begins when a trio of space looters boards the Leviathan’s derelict wreckage. While exploring the abandoned ship, the scavengers find a hidden diary belonging to a child named Kazuma. The journal slowly unfurls the harrowing, blood-soaked account of the passengers’ final hours. Originally serialized in Shonen Jump+ from 2022 to 2023, the manga earned massive acclaim for its psychological horror.
Creative Team and Cast
Directors Michihito Fujii and Ryohei Shingu co-directed the live-action feature adaptation. Fujii also co-wrote the intense screenplay with screenwriter Izumi Takahashi. Popular actors Shunsuke Michieda and Natsuki Deguchi lead the cast.
Global Release Details
The sci-fi survival film officially debuts in Japanese theaters on February 11, 2027. Meanwhile, Paris-based sales company Goodfellas is handling international distribution outside of Asia. The team plans to showcase initial footage at the American Film Market to secure global release deals. Stay tuned for updates and more details.
